People with elevated red blood cell counts or hematocrit levels face a measurably higher risk of developing type 2 diabetes, and once diabetes is established, the disease reshapes red blood cells in ways that feed back into its own complications. Large prospective studies have found that individuals in the highest range of hematocrit carry roughly three to four times the diabetes risk of those in the lowest range, even after accounting for weight and other metabolic factors. The relationship runs in both directions and involves everything from blood thickness to how diabetes drugs alter red cell production.
High Hematocrit as a Risk Factor for Type 2 Diabetes
The idea that a high red blood cell count might predict future diabetes goes back decades. One of the clearest demonstrations came from a study of middle-aged men that tracked them over several years. Men whose hematocrit topped 48 percent had nearly four times the risk of developing type 2 diabetes compared with men below 42 percent, after adjusting for age, body mass index, and other known risk factors.1PubMed. Hematocrit and risk of NIDDM That finding held up in larger, more diverse populations. The Atherosclerosis Risk in Communities (ARIC) study, which followed thousands of adults across four U.S. sites, found that people in the top quarter of hematocrit had about 63 percent higher risk of incident type 2 diabetes compared with the bottom quarter, with a clear dose-response gradient across the range.2PubMed Central. Blood Viscosity and Hematocrit as Risk Factors for Type 2 Diabetes Mellitus
A separate line of evidence involves metabolic syndrome, the cluster of conditions including abdominal obesity, high blood pressure, abnormal cholesterol, and elevated blood sugar that frequently precedes diabetes. A systematic review and meta-analysis pooling data from roughly 170,000 patients found that people with metabolic syndrome had significantly higher red blood cell counts, hemoglobin levels, and red cell distribution width compared with controls.3PubMed. Association of Red Blood Cell and Platelet Parameters with Metabolic Syndrome: A Systematic Review and Meta-Analysis of 170,000 Patients The elevations were consistent across study populations, suggesting that higher red cell mass is part of the metabolic syndrome package rather than a coincidental finding.
Why Thicker Blood Raises Diabetes Risk
The leading explanation centers on blood viscosity. More red cells make blood thicker, and thicker blood flows more slowly through small vessels. That sluggish flow reduces how much insulin and glucose actually reach skeletal muscle, which is the body’s main site for using glucose. The body tries to compensate by widening blood vessels and raising blood pressure, but once those adjustments are maxed out, the only way to push enough insulin and glucose through to the muscles is to raise their concentrations in the bloodstream. The result looks a lot like the early stages of insulin resistance: blood sugar and insulin levels climb even though the underlying problem is delivery, not the pancreas or the muscle tissue itself.4PubMed Central. Blood Viscosity and Hematocrit as Risk Factors for Type 2 Diabetes Mellitus – Section: DISCUSSION
This viscosity pathway also helps explain why elevated hematocrit tends to cluster with other cardiovascular risk factors. Higher blood viscosity promotes endothelial stress, and red blood cells themselves play an active role in clot formation by influencing platelet behavior, altering the structure of fibrin clots, and affecting nitric oxide availability in the vessel wall.1PubMed. Hematocrit and risk of NIDDM The researchers behind the original hematocrit-diabetes studies argued that elevated hematocrit should be added to the cluster of risk factors linking type 2 diabetes with vascular disease, alongside the usual suspects of high blood pressure, abnormal lipids, and obesity.
Insulin Resistance Pushes Red Cell Counts Up Too
The relationship is not one-directional. Insulin resistance itself appears to raise red blood cell counts, creating a feedback loop. A study examining people across the full spectrum of insulin sensitivity found that red blood cell count, hemoglobin, hematocrit, and plasma iron all correlated with the degree of insulin resistance. People in the highest quarter of insulin resistance had higher red cell counts, higher triglycerides, and higher LDL cholesterol than those in the lowest quarter. Insulin resistance and BMI were independent predictors of red blood cell count even after adjusting for age, sex, waist-to-hip ratio, iron levels, and medication use.5PubMed. New aspects of the insulin resistance syndrome: impact on haematological parameters
One mechanism behind this involves the renin-angiotensin system, which is significantly more active in people with diabetes. Angiotensin II, the system’s main signaling molecule, causes oxygen levels to drop in the tissue surrounding kidney tubules. That local hypoxia triggers the kidney’s oxygen-sensing machinery, which responds by ramping up production of erythropoietin, the hormone that tells bone marrow to make more red blood cells.6American Journal of Nephrology. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes So the metabolic environment of diabetes and insulin resistance can directly stimulate the body to produce extra red blood cells, which then thickens the blood and worsens the delivery problems described above.
How Diabetes Changes Red Blood Cells Themselves
Beyond the question of how many red cells you have, diabetes also changes how those cells behave. Chronic high blood sugar modifies the red blood cell membrane, affecting its composition, flexibility, and stability. These changes alter how ions move in and out of the cell and disrupt enzymes embedded in the membrane. The practical consequence is that diabetic red blood cells are stiffer than healthy ones. They have a harder time squeezing through the tiniest blood vessels, capillaries barely wider than the cells themselves, which impairs blood flow at the tissue level.7PubMed Central. Red blood cells as biomarkers and mediators in complications of diabetes mellitus: A review
This reduced deformability has been directly measured. Using laser-based stretching techniques on individual red blood cells, researchers have shown that cells from people with type 2 diabetes are significantly less deformable than those from healthy controls, and cells from people with diabetic retinopathy are stiffer still.8Scientific Reports. Assessment of red blood cell deformability in type 2 diabetes mellitus and diabetic retinopathy by dual optical tweezers stretching technique Stiffer red cells compound the viscosity problem: not only is there potentially more blood volume, but the individual cells create more friction and resistance as they travel through microvessels. This contributes to the microvascular damage that underlies many of diabetes’s most feared complications, including damage to the eyes, kidneys, and nerves.
The Retinopathy Puzzle
Here is where the picture gets counterintuitive. While a high red blood cell count before diagnosis may signal greater diabetes risk, once someone has diabetes, low hemoglobin and hematocrit are associated with worse eye disease. Studies of people with type 2 diabetes have found that hemoglobin, hematocrit, and blood viscosity are all significantly lower in those with retinopathy compared with those without, and that these values drop further as retinopathy becomes more severe.9PubMed. Association among low whole blood viscosity, haematocrit, haemoglobin and diabetic retinopathy in subjects with type 2 diabetes
A large study of Korean adults with type 2 diabetes found that every 1 g/dL increase in hemoglobin was associated with a 19 percent decrease in retinopathy risk, with a clear trend toward lower risk at higher hemoglobin levels.10Scientific Reports. High hemoglobin levels are associated with decreased risk of diabetic retinopathy in Korean type 2 diabetes This is partly because anemia reduces the oxygen-carrying capacity of blood. The retina is one of the most metabolically demanding tissues in the body, and when hemoglobin drops, the retina suffers disproportionately. In a small clinical study, treating anemia with erythropoietin to raise hematocrit from about 30 percent to about 40 percent led to documented improvement in macular edema in several patients.11PubMed. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease
The practical takeaway is that the relationship between red cell levels and diabetes complications is not as simple as “high is bad” or “low is bad.” Before diabetes develops, elevated hematocrit is a warning sign. After diabetes is established and kidney function begins to decline, falling hemoglobin can accelerate damage to the eyes and other vulnerable tissues. Clinicians watching a diabetic patient’s blood work need to pay attention to movement in either direction.
How Diabetes Medications Shift Red Blood Cell Counts
Two of the most commonly prescribed diabetes drugs have opposite effects on red blood cell parameters, and understanding those shifts matters for interpreting lab results.
SGLT2 inhibitors, a class of drugs that includes dapagliflozin, empagliflozin, and canagliflozin, reliably raise hematocrit. The mechanism is twofold. First, these drugs cause the kidneys to excrete extra glucose and sodium in the urine, pulling water along and reducing plasma volume. This concentrating effect alone accounts for some of the hematocrit rise. A study comparing dapagliflozin with a standard diuretic found that hematocrit increased by about 2.2 percentage points with dapagliflozin, compared to a slight decrease with the diuretic.12Frontiers in Endocrinology. Comprehensive review of SGLT2 inhibitors’ efficacy through their diuretic mode of action in diabetic patients But the second mechanism is more interesting: SGLT2 inhibitors actually stimulate the kidneys to make more erythropoietin. By shifting work from the early part of the kidney tubule to deeper segments that happen to sit near the oxygen-sensing cells that produce erythropoietin, these drugs trick those cells into sensing low oxygen, even without actual systemic hypoxia. The result is genuinely increased red blood cell production, not just a concentrating effect.13PubMed Central. Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys
A large real-world study confirmed that hematocrit rose by a median of about 2.1 percentage points after SGLT2 inhibitor treatment began, with a somewhat larger increase in men than women. Anemia prevalence in the study population dropped from roughly 32 percent before treatment to 20 percent after. Gender, smoking status, the specific SGLT2 inhibitor used, baseline hematocrit, diabetes duration, BMI, and kidney function all influenced the degree of hematocrit change. Researchers have described this as “unmasking” a suppressed anemia, essentially restoring red cell production that had been blunted by the diabetic kidney environment. This hematocrit bump is now considered one mechanism behind the cardiovascular benefits these drugs have shown in clinical trials, since improved oxygen delivery and reduced plasma volume both ease the workload on the heart.
Metformin, the most widely used first-line diabetes drug, pushes in the other direction. Long-term metformin use is associated with vitamin B12 deficiency, which can lead to anemia. Because B12 is essential for normal red blood cell production, metformin-related depletion can reduce red cell counts and hemoglobin over time.14PubMed Central. The Impact of Glycemic Status and Metformin Administration on Red Blood Cell Indices and Oxidative Stress in Type 2 Diabetic Patients For someone on both metformin and an SGLT2 inhibitor, these opposing forces can partially cancel each other out, which can make changes in blood work harder to interpret without knowing the patient’s full medication list.
When HbA1c Results Mislead
HbA1c, the standard test used to measure average blood sugar over the previous two to three months, works by measuring how much glucose has attached to hemoglobin inside red blood cells. That means anything that changes the lifespan or turnover rate of red cells will alter the result, potentially in misleading ways. If red blood cells live longer than normal, they accumulate more glucose and HbA1c reads falsely high. If red cells are destroyed or replaced faster than normal, HbA1c reads falsely low.
This is clinically important in diabetes care. Iron deficiency anemia, vitamin B12 deficiency, and folate deficiency can all prolong the average red cell lifespan, pushing HbA1c readings upward and making blood sugar control look worse than it actually is. Treatment of iron deficiency anemia has been shown to lower HbA1c even when blood sugar itself has not changed. On the other hand, conditions that shorten red cell lifespan, including some hemoglobin variants and hemolytic anemias, can pull HbA1c down and mask poor control.15PubMed Central. Pitfalls in Hemoglobin A1c Measurement: When Results may be Misleading For people whose red blood cell counts are shifting, whether from SGLT2 inhibitors stimulating new production, metformin-related B12 depletion, or kidney disease causing anemia, HbA1c results deserve an extra layer of scrutiny. Fructosamine testing or continuous glucose monitoring can provide a cross-check when the red cell picture is unstable.
Overlapping Conditions That Raise Both Red Cells and Metabolic Risk
Several conditions common among people with diabetes or prediabetes independently elevate red blood cell parameters, creating a tangle of overlapping signals.
Obstructive sleep apnea, which is extremely common in people with type 2 diabetes, is one. Repeated drops in blood oxygen during the night stimulate erythropoietin production, pushing red cell counts and hematocrit up. A study analyzing blood cell profiles across different severities of sleep apnea found that hematocrit was independently associated with the severity of the condition.16PubMed Central. The association of hemocyte profile and obstructive sleep apnea Someone with undiagnosed sleep apnea who shows up with a high hematocrit might be flagged as metabolically at risk, and they would be correct to worry, but the sleep apnea itself could be a treatable cause of the elevated red cells.
Non-alcoholic fatty liver disease (NAFLD) is another condition that overlaps heavily with insulin resistance and diabetes. Red blood cell count, hematocrit, and hemoglobin all show significant positive correlations with insulin resistance and NAFLD. Hemoglobin, ferritin, and triglycerides were independent predictors of fatty liver in multivariate analysis.17PubMed. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver In children and adolescents with NAFLD, the connection extends further: those with the more aggressive form of the disease, called NASH, had significantly higher red cell counts, hemoglobin, hematocrit, and red cell distribution width than those with simple fatty liver.18PubMed. Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease Whether elevated red cell parameters in these patients are a cause, a consequence, or simply a fellow traveler of the underlying metabolic disturbance remains an open question, but their presence can serve as a useful clinical signal that metabolic health deserves closer attention.
Red Blood Cells as Active Players in Blood Sugar Regulation
For most of the history of diabetes research, red blood cells were treated as passive bystanders, bags of hemoglobin that happened to pick up glucose. Recent work is challenging that view. A 2025 study in Cell Metabolism demonstrated that red blood cells actively take up glucose in response to low oxygen and function as a significant “glucose sink” in the body. Researchers studying mice under low-oxygen conditions found that the animals developed more red cells and lower blood sugar. When they counteracted the extra red cell production through repeated blood draws to normalize hematocrit, blood sugar rose back toward normal levels and the improvement in glucose tolerance disappeared. Transfusing red blood cells into normal mice caused marked drops in blood sugar, with cells adapted to low-oxygen conditions producing a slightly greater effect.19Cell Metabolism. Red blood cells regulate systemic glucose homeostasis and rescue hyperglycemia in diabetes This is still early-stage research in animal models, but it suggests that the connection between red cell mass and blood sugar may be more fundamental than a simple viscosity story. If red blood cells actively regulate how much glucose is available in the bloodstream, then shifts in red cell count, whether from disease, medication, altitude, or fitness level, could have direct metabolic consequences that we are only beginning to map.